Advertisement

Assessing Cardiovascular Disease Risk and Responses to Preventive Therapies in Clinical Practice

  • Kevin C. Maki
  • Mary R. Dicklin
Nutrition (P. Kris-Etherton, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Nutrition

Abstract

Purpose of Review

The aims of this review are to provide perspective on evaluation of relative and absolute cardiovascular disease (CVD) risk reductions for assessing the efficacy of preventive therapies and to summarize methods for evaluation of CVD risk in clinical practice.

Recent Findings

Major CVD risk factors can be used to stratify patients into risk categories. Results from recent trials reinforce the view that benefits of preventive therapies will be greatest in those with the highest absolute risk and in those with the most severe disturbance in the risk factor targeted. In evaluating clinical utility, it is necessary to assess the impact of an intervention on both relative and absolute risk. Quantitative risk scoring using major CVD risk factors is effective for identifying those at low, moderate, and high CVD risk. When there is uncertainty about the appropriate treatment strategy, additional testing may be used to refine risk assessment. This may include measurement of inflammatory markers, subclinical indicators of atherosclerosis (e.g., coronary artery calcium and ankle brachial index), urinary albumin/creatinine ratio, and the level of lipoprotein (a).

Summary

The benefit of a preventive therapy will generally be the greatest in those with the highest absolute risk and in those with the most severe disturbance in the risk factor targeted. Quantitative risk scoring with major CVD risk factors can be supplemented with additional testing for refinement of risk assessment in patients for whom decisions about pharmacotherapy, or the intensity of therapy, for risk factor modification are uncertain.

Keywords

Cardiovascular risk Risk assessment Risk factors Lipoprotein lipids Inflammation Subclinical cardiovascular biomarkers 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Maki reports grants and personal fees from Amgen, grants and personal fees from AstraZeneca, personal fees from Kowa, personal fees from Quest Laboratories, and grants from Regeneron, outside the submitted work. Dr. Dicklin reports grants from Amgen, AstraZeneca, and Regeneron, outside the submitted work.

Human and Animal Rights and Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •Of importance •• Of major importance

  1. 1.
    Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78.CrossRefPubMedGoogle Scholar
  2. 2.
    National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel) III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.Google Scholar
  3. 3.
    Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.CrossRefPubMedGoogle Scholar
  4. 4.
    • Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9(2):129–69. Full report of the most recent CVD risk assessment and dyslipidemia management guidelines from the NLA. CrossRefPubMedGoogle Scholar
  5. 5.
    •• HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszuz K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27. Latest outcome trial of a CETP inhibitor. CrossRefGoogle Scholar
  6. 6.
    •• Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. Results from FOURIER, the first cardiovascular outcome trial of a PCSK9 inhibitor. CrossRefPubMedGoogle Scholar
  7. 7.
    •• Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2017 [Epub ahead of print]. The most recent blood pressure guidelines from the ACC/AHA Task Force on clinical practice guidelines.Google Scholar
  8. 8.
    Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Sharifi M, Rakhit RD, Humphries SE, Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart. 2016;102(13):1003–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC Jr, et al. Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis. Pediatrics. 2006;118(4):1447–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Nordestgaard BG. Triglyceride-rich lipoprotein and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547–63.CrossRefPubMedGoogle Scholar
  12. 12.
    White J, Swerdlow DI, Preiss D, Fairhurst-Hunter Z, Keating BJ, Asselbergs FW, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol. 2016;1(6):692–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Vitali C, Khetarpal SA, Rader DJ. HDL cholesterol metabolism and the risk of CHD: new insights from human genetics. Curr Cardiol Rep. 2017;19(12):132.CrossRefPubMedGoogle Scholar
  14. 14.
    • Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88. Executive summary of the most recent CVD risk assessment and dyslipidemia management guidelines from the NLA. CrossRefPubMedGoogle Scholar
  15. 15.
    Barter PJ, Rye KA. Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence? Clin Ther. 2015;37(12):2716–31.CrossRefPubMedGoogle Scholar
  16. 16.
    •• Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935–59. The most recent full CVD risk assessment guidelines from the ACC/AHA. CrossRefPubMedGoogle Scholar
  17. 17.
    • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(Pt B):2889–934. The most recent full cholesterol management guidelines from the ACC/AHA. CrossRefPubMedGoogle Scholar
  18. 18.
    Paneni F, Luscher TF. Cardiovascular protection in the treatment of type 2 diabetes: a review of clinical trial results across drug classes. Am J Cardiol. 2017;120(1S):S17–27.CrossRefPubMedGoogle Scholar
  19. 19.
    • Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol. 2015b;9(6 Suppl):S1–122. Continuation of the most recent dyslipidemia management guidelines from the NLA that include recommendations regarding lifestyle therapies, groups with special considerations, and strategies to increase adherence. CrossRefPubMedGoogle Scholar
  20. 20.
    Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2960–84.CrossRefPubMedGoogle Scholar
  21. 21.
    American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 2017;40(Suppl 1):S1–135.Google Scholar
  22. 22.
    Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408–16.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    •• Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31. Results from the proof-of-concept CANTOS study demonstrating that lowering inflammation reduces risk for CVD. CrossRefPubMedGoogle Scholar
  24. 24.
    •• Ridker PM, MacFadyen J, Everett B, Libby P, Thuren T, Glynn R. on behalf of the worldwide investigators and participants in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Residual inflammatory risk and residual cholesterol risk: critical analysis from CANTOS. Relationship of CRP reduction to cardiovascular event reduction following treatment with canakinumab. Slides presented at the American Heart Association 2017. Accessed on November 30, 2017 at http://www.clinicaltrialresults.com/Slides/AHA2017/CANTOS_Ridker.pdf. Presentation of the CANTOS results at the 2017 AHA meeting.
  25. 25.
    Ridker PM, Danielson E, Fonseca FA, Genest H, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.CrossRefPubMedGoogle Scholar
  26. 26.
    Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224–33.CrossRefPubMedGoogle Scholar
  27. 27.
    McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors. Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66(15):1643–53.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    • Gupta A, Lau E, Varshney R, Hulten EA, Cheezum M, Bittencourt MS, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10(8):833–42. Recent systematic review and meta-analysis of the use of CAC CrossRefPubMedGoogle Scholar
  29. 29.
    Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–45.CrossRefPubMedGoogle Scholar
  30. 30.
    Mora S, Buring JE, Ridker PM. Discordance of LDL cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol. 2014;8(1):29–60.CrossRefGoogle Scholar
  32. 32.
    Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev. 2017;2017:1273042.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Toth PP. Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr Vasc Pharmacol. 2014;12(4):653–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Despres JP, Ndumele CE, et al. The CardioMetabolic Health Alliance. Working toward a new care model for the metabolic syndrome. J Am Coll Cardiol. 2015;66(9):1050–67.CrossRefPubMedGoogle Scholar
  35. 35.
    Munnur RK, Nerlekar N, Wong DT. Imaging of coronary atherosclerosis in various susceptible groups. Cardiovasc Diagn Ther. 2017;6(4):382–95.CrossRefGoogle Scholar
  36. 36.
    Meyer KA, Bennett BJ. Diet and gut microbial function in metabolic and cardiovascular disease risk. Curr Diab Rep. 2016;16(10):93.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Midwest Biomedical Research: Center for Metabolic and Cardiovascular HealthGlen EllynUSA

Personalised recommendations